Laboratory-based surveillance of pertussis using multitarget real-time PCR in Japan: evidence for Bordetella pertussis infection in preteens and teens

K. Kamachi¹, S. Yoshino², C. Katsukawa³, N. Otsuka¹, Y. Hiramatsu¹ and K. Shibayama¹
¹) Department of Bacteriology II, National Institute of Infectious Disease, Tokyo, 2) Department of Microbiology, Miyazaki Prefectural Institute for Public Health and Environment, Miyazaki and 3) Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, Osaka, Japan

Abstract

Between January 2013 and December 2014, we conducted laboratory-based surveillance of pertussis using multitarget real-time PCR, which discriminates among Bordetella pertussis, Bordetella parapertussis, Bordetella holmesii and Mycoplasma pneumoniae. Of 355 patients clinically diagnosed with pertussis in Japan, B. pertussis, B. parapertussis and M. pneumoniae were detected in 26% (n = 94), 1.1% (n = 4) and 0.6% (n = 2), respectively, whereas B. holmesii was not detected. It was confirmed that B. parapertussis and M. pneumoniae are also responsible for causing pertussis-like illness. The positive rates for B. pertussis ranged from 16% to 49%, depending on age. Infants aged ≤3 months had the highest rate (49%), and children aged 1 to 4 years had the lowest rate (16%, p < 0.01 vs. infants aged ≤3 months). Persons aged 10 to 14 and 15 to 19 years also showed high positive rates (29% each); the positive rates were not statistically significant compared with that of infants aged ≤3 months (p ≥ 0.06). Our observations indicate that similar to infants, preteens and teens are at high risk of B. pertussis infection.

New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Keywords: Bordetella holmesii, Bordetella parapertussis, Bordetella pertussis, Mycoplasma pneumoniae, pertussis, real-time PCR

Original Submission: 24 June 2015; Revised Submission: 5 October 2015; Accepted: 5 October 2015
Article published online: 22 October 2015

Introduction

Pertussis (whooping cough) is a major acute respiratory infection caused by Bordetella pertussis bacteria and is associated with severe respiratory illness in children and persistent cough in adolescents and adults. The most effective method to prevent and control pertussis is immunization; however, the incidence of pertussis has increased in several developed countries despite high vaccination coverage [1]. Bordetella parapertussis and Bordetella holmesii, which are closely related to B. pertussis, also cause pertussis-like coughs [2,3]. Acellular pertussis vaccines (ACVs) have little or no protection against B. parapertussis and B. holmesii infections, both of which have been detected recently with significant percentages in pertussis-like illness [4–6]. In addition, Mycoplasma pneumoniae is a bacterial agent of atypical pneumonia in children and adults that also causes a persistent pertussis-like cough [7]. The clinical diagnosis of B. pertussis infection is complicated by other respiratory pathogens [8].

In Japan, the incidence of pertussis cases in adolescents and adults has significantly increased since the early 2000s, and a large pertussis epidemic occurred between 2008 and 2010 despite high vaccination coverage with ACVs [9]. A total of 17,349 cases were reported from approximately 3000 sentinel clinics and hospitals in the epidemic. The national pertussis surveillance data regarding individuals diagnosed mainly on the basis of clinical symptoms, bacterial culture and/or serologic testing are collected. In comparison to culture and serology, which are the classic tests for pertussis diagnosis, nucleic acid amplification tests have improved sensitivity and specificity; however, these tests have not yet been widely introduced into
Japan. Therefore, our laboratory, a national reference laboratory for pertussis, developed a multitarget real-time PCR assay (4Plex RT-PCR) to discriminate among B. pertussis, B. parapertussis, B. holmesii and M. pneumoniae and then introduced the assay into our diagnostic service starting in January 2013. The present study reports 2 years of experience of the service for 355 patients with clinically suspected pertussis.

**Materials and Methods**

**Clinical specimens**

Between January 2013 and December 2014, we conducted a laboratory-based surveillance study of 355 patients clinically diagnosed with pertussis. Clinical specimens (nasopharyngeal swab or aspirate) were collected at 19 medical institutions in Japan. All the nasopharyngeal aspirates (2% of the total number of specimens) were collected from young infants hospitalized with severe respiratory distress. The specimens were transported to the National Institute of Infectious Diseases, Japan. Nasopharyngeal swabs were immersed in 0.5 mL of saline, vortexed and subjected to centrifugation (20,000 × g for 10 minutes). Nasopharyngeal aspirates (50–100 μL) were suspended in 1 mL of saline, vortexed, and centrifuged at the same conditions. Total DNA was extracted from the pellet using the QIAamp DNA Micro kit (Qiagen) and eluted with 25 μL of the AE elution buffer. If several specimens were received from a single patient, they were tested separately. The overall result was considered positive if any of these specimens tested positive.

In Japan, pertussis cases are reported based on clinical diagnosis. The clinical criteria are cough lasting for ≥2 weeks with one or more of the following symptoms: whoop and staccato cough, apneic paroxysm or posttussive vomiting. However, in the present study, patients were clinically diagnosed based on their physician’s judgement, so not all patients met the reporting criteria.

This study was considered exempt from institutional review board approval because clinical specimens were obtained for diagnostic and surveillance purposes.

**4Plex RT-PCR**

Target sequences of the 4Plex RT-PCR were insertion sequence IS481 (detection for B. pertussis and B. holmesii), recA (B. holmesii), IS1001 (B. parapertussis) and atpD (M. pneumoniae). Published primers and probes were used for recA and atpD [10,11], and those for IS481 and IS1001 were used with minor modifications [12] (Table 1). 4Plex RT-PCR was performed using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). The PCR amplifications were carried out in 20 μL reaction volumes containing 10 μL of 2× Premix EX Taq (Perfect Real Time, Takara Bio), 0.2 μL of 50× ROX reference dye II, 2 μL of DNA samples and optimized concentrations of primers and probes (Table 1). The PCR conditions were 10 s at 95°C, followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. The cutoff threshold ΔRn (relative fluorescent intensity) value was set to 0.3 for all fluorescence signals, and the sample was considered positive with a change in ΔRn of ≥ 0.3, corresponding to a threshold cycle (Ct) cutoff value of approximately 36 with automatic calculation. In each assay, purified DNAs (10 pg of B. pertussis Tohama, 100 pg of B. holmesii ATCC51542, 10 pg of B. parapertussis BAA-587, 1 pg of M. pneumoniae NBRC14401) were used as positive controls, whereas the negative control was sterile distilled water. The analytical sensitivities of the assay were not affected by multiplexing (Supplemental Fig. S1). The measured PCR amplification efficiencies of 98% to 103% for the targets B. holmesii IS481 and recA and M. pneumoniae atpD were in good agreement with the

| Target gene (organism) | Primer or probe | Sequence (5’ to 3’) | Reporter/quencher | Amplicon (bp) | Optimal concentration (nM) | Reference |
|------------------------|----------------|---------------------|-------------------|---------------|-----------------------------|-----------|
| IS481 (Bordetella pertussis and Bordetella holmesii) | PerfM | ATCAAGCACCAGTCTTACCACG | 114 | 300 | 12 |
| | APen | TGGAGCTCTCTGTGATGTC | 300 | | |
| recA (B. holmesii) | SPen | CAAAGCCGAACCTGTT | 200 | | |
| | BREC-A-F | CGGTTGGCTGGTGCTCG | 50 | 400 | 10 |
| | BREC-A-R | CCCGCGGCCAGACACG | | | |
| | BREC-A-P | CATCAGATGGGCGG | 200 | | |
| IS1001 (B. parapertussis) | PParaP | GATATCAACCGCTTTACCG | 103 | 300 | 12 |
| | AParaP | GATGCCCAACCCCAATGCG | 300 | | |
| | SPen | TGGACTCAGACCAACG | 100 | | |
| atpD (M. pneumoniae) | Mp3-F | CGTATCTATGTCGCACTGTA | 68 | 200 | 11 |
| | Mp3-R | AGCATCAAGGTGGTAAAAGGT | 200 | | |
| | Mp3-P | TTTGACGACCAGCGTCGCGC | Cy5/BHQ3 | 100 | | |

*aOligonucleotide length was modified.*

*bNon-Fluorescent Quencher-Minor Groove Binder.*

*cBlack Hole Quencher 3.*

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
theoretical value of 100%. The efficiencies for \(B. \) pertussis IS481 and \(B. \) parapertussis IS1001 showed somewhat higher values (116–117%), the reason for which is currently unclear.

In the 4Plex RT-PCR assay, \(B. \) pertussis infection was defined as positive for IS481 and negative for recA (IS481+recA−), whereas \(B. \) holmesii was defined as positive for both IS481 and recA (IS481+recA+). \(B. \) parapertussis and \(M. \) pneumoniae were defined as positive for IS1001 and atpD, respectively.

**Statistical analysis**

Data were analysed by Fisher’s exact test. A value of \(p < 0.05\) was considered statistically significant.

**Results**

Among 355 patient samples, 94 (26%), four (1.1%) and two (0.6%) were positive for \(B. \) pertussis, \(B. \) parapertussis and \(M. \) pneumoniae, respectively. There was no incidence of coinfection with those organisms. No positive samples for \(B. \) holmesii were detected, but 4Plex RT-PCR targeting recA is less sensitive than IS481. Fig. 1 shows the monthly distribution of samples testing positive using PCR. \(B. \) pertussis-positive samples were observed in relatively large numbers from April to June 2014 (34% of the total) and also showed a tendency to decrease in the winter season from December to February. Four \(B. \) parapertussis-positive samples were detected in 2013. All of them were collected in the same hospital, with no apparent seasonal variations. Two \(M. \) pneumoniae-positive samples were detected in October 2013 and 2014, and confirmed using a separate genetic test (Loopamp Mycoplasma P Detection Kit; Eiken Chemical, Japan). Our pertussis surveillance data did not fully correspond with national pertussis surveillance data, especially in the period from April to August 2014.

As shown in Table 2, of 94 \(B. \) pertussis-positive samples, 21 were from infants aged ≤3 months, and 20 were from children aged 5 to 9 years. Of four \(B. \) parapertussis-positive samples, three and one were from children aged 1 to 4 years and 5 to 9 years, respectively. Similarly, two \(M. \) pneumoniae-positive samples belonged to the same age groups. Fig. 2 shows positive rates for \(B. \) pertussis by age group. Infants aged ≤3 months had the highest rate (49%), whereas children aged 1 to 4 years had...
The age distribution of PCR-positive rates for Bordetella pertussis. Total of 93 patients of known age were classified into seven age groups (Table 2). Statistically significant differences (Fisher’s exact test) between infants aged ≤ 3 months (reference) and other age groups are indicated by asterisks (*p < 0.05; **p < 0.01). Age groups not significantly different from reference group are indicated by NS. M, months; Y, years.

Discussion

This study confirmed that B. pertussis is the most common aetiologic agent in cases of suspected pertussis and that B. parapertussis and M. pneumoniae are also responsible for causing a small proportion of pertussis-like illnesses. In this study, no positive samples for B. holmesii were detected, although respiratory infection with B. holmesii has recently increased worldwide [3,5,6]. 4Plex RT-PCR has high analytical sensitivities for B. pertussis, B. parapertussis and M. pneumoniae (detection limits of 10–100 fg genomic DNA), but it has a relatively low sensitivity for B. holmesii recA (detection limit of 1 pg DNA, corresponding to a Ct value of 35.6). We therefore cannot exclude the possibility that some patients could have low B. holmesii DNA loads (Ct value of > 35.6) in their clinical specimens. However, we previously reported that patients not treated with antibiotics had high B. holmesii DNA loads (Ct values of 21.6 to 28.7) in their nasopharyngeal swab samples [5]. Thus, 4Plex RT-PCR has sufficient sensitivity to detect B. holmesii in clinical specimens. A recent study has found that an increasing number of B. holmesii bacteraemia cases were associated with outbreaks of B. pertussis [13]. This suggests that B. holmesii epidemics occur periodically, similar to B. pertussis. In Japan, a B. pertussis epidemic has not occurred from 2011 to the present; hence, continuous laboratory-based surveillance is required for B. holmesii.

In the present study, B. pertussis–positive samples were detected from individuals over a wide age range, consistent with previous reports [14–17]. Infants aged ≤ 3 months had the highest positive rate (49%); interestingly, persons aged 10 to 14 and 15 to 19 years also showed high positive rates (each 29%). In Japan, ACVs are used to control pertussis with a schedule of three primary doses and a single booster dose at ages 3, 4, 6 and 18 to 23 months, respectively. The vaccination is done under the Japanese Preventive Vaccination Law, and consequently immunization rates among children are high (≥ 90%). The duration of immunity after vaccination is estimated to be in the range of 4 to 12 years [18,19]; accordingly, preteens and teens are considered to be at high risk of B. pertussis infection. Our data provide support for the waning immunity in the second decade of life. Moreover, this study also demonstrates that children aged 1 to 4 years had the lowest positive rate (16%). This age group covers children from the age where they have received at least three doses of ACVs. The herd immunity against B. pertussis would be well maintained in the age group of 1 to 4 years. The lack of detailed clinical information (e.g., duration of cough, time of specimen collection and time of onset of symptoms) makes it difficult to explain why the B. pertussis–positive rate is equally low (18%) in the ≥ 20 years age group.

Recent genomic analyses revealed that some Bordetella bronchiseptica isolates (a broad-host-range pathogen) harbor IS481 and/or IS1001 [20]. This implies that B. bronchiseptica cannot be discriminated from B. pertussis and B. parapertussis using 4Plex RT-PCR. However, B. bronchiseptica infection in humans is rare [21,22]; are only two case reports exist from Japan. Therefore, we believe that B. bronchiseptica infection is negligible in our results.

In conclusion, we successfully used 4Plex RT-PCR for the surveillance of pertussis in Japan. Additionally, we confirmed that, similar to infants, preteens and teens are at high risk of B. pertussis infection. The 4Plex RT-PCR described here has become a practical tool for detection of pertussis, and therefore we have started supplying the 4Plex RT-PCR kit to Japanese prefectural and municipal public institutes for regional surveillance.

Acknowledgements

We thank H. Toyoizumi-Ajisaka and M. Shibata for their technical support. This study was supported by grants for
Research on Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor and Welfare of Japan.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.nmni.2015.10.001.

Conflict of Interest

None declared.

References

[1] Libster R, Edwards KM. Re-emergence of pertussis: what are the solutions? Expert Rev Vaccines 2012;11:1331–46.
[2] Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326–82.
[3] Pittet LF, Emonet S, Schrenzel J, Siegrist CA, Posfay-Barbe KM. Bordetella holmesii: an under-recognised Bordetella species. Pediatr Infect Dis J 2014;34:510–9.
[4] Cherry JD, Seaton BL. Patterns of pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 2005;24:S25–34.
[5] Miyaji Y, Otsuka N, Toyoizumi-Ajisaka H, Shibayama K, Kamachi K. Genetic analysis of Bordetella pertussis isolates from the 2008–2010 pertussis epidemic in Japan. PLoS One 2013;8:e77165.
[6] Pittet LF, Emonet S, Francois P, Bonetti EJ, Schrenzel J, Hug M, et al. Diagnosis of whooping cough in Switzerland: differentiating Bordetella pertussis from Bordetella holmesii by polymerase chain reaction. PLoS One 2014;9:e88936.
[7] Fry NK, Duncan J, Wagner K, Tzivra O, Doshi N, Litt DJ, et al. Role of PCR in the diagnosis of pertussis infection in infants: 5 years’ experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007. J Med Microbiol 2009;58:1023–9.
[8] Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24:558–61.
[9] Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al. Waning immunity to pertussis following 5 doses of DTPa. Pediatrics 2010;125:1047–52.
[10] Tizolova A, Guiso N, Guillot S. Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome. Eur J Clin Microbiol Infect Dis 2013;32:89–96.
[11] Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol 2008;46:3116–8.
[12] Kösters K, Riffelmann M, Wirsing von König CH. Evaluation of a real-time PCR assay for detection of Bordetella pertussis and B. parapertussis in clinical samples. J Med Microbiol 2001;50:436–40.
[13] Tartof SY, Gounder P, Weiss D, Lee L, Cassidy PK, Clark TA, et al. Bordetella holmesii bacteremia cases in the United States, April 2010–January 2011. Clin Infect Dis 2014;58:e39–43.
[14] Dragsted DM, Dohn B, Madsen J, Jensen JS. Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions. J Med Microbiol 2004;53:749–54.
[15] Waites KB, Talkington DF. Mycoplasma pneumoniae and other Mycoplasma species in respiratory tract samples from Belgian patients with pertussis-like symptoms in 2003–2004. J Med Microbiol 2005;54:199–205.
[16] Kamiya H, Otsuka N, Ando Y, Odaira F, Yoshino S, Kawano K, et al. Transmission of Bordetella holmesii during pertussis outbreak, Japan. Emerg Infect Dis 2012;18:1166–9.
[17] Rodgers L, Martin SW, Cohn A, Budd J, Marcon M, Terranella A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis—Ohio, 2010–2011. Clin Infect Dis 2013;56:322–31.
[18] Burgos-Rivera B, Lee AD, Bowden KE, Faulkner AE, Seaton BL, Lembo BD, et al. An evaluation of the level of agreement in Bordetella species identification in three United States laboratories during a period of increased pertussis. J Clin Microbiol 2015;53:1842–7.